PRC
IPXL

Platte River Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Platte River Capital’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-59,940
Closed -$1.2M – 233
2013
Q2 		$1.2M Buy
+59,940
New +$1.06M 0.14% 144

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Platte River Capital's IPXL Position: Q3 2013 in Review

Platte River Capital sold out of Impax Laboratories, Inc. (IPXL) in Q3 2013, closing a stake of 59,940 shares — an estimated $1.2M sold.

Platte River Capital first reported a position in IPXL in Q2 2013 and held it in 1 quarter. The position peaked at $1.2M in Q2 2013. 158 funds tracked by Wall St. Rank hold IPXL as of Q3 2013.

  • Platte River Capital reported no remaining Impax Laboratories, Inc. position as of Q3 2013 after selling out during the quarter.
  • Platte River Capital sold 59,940 Impax Laboratories, Inc. shares in Q3 2013, an estimated $1.2M.
  • Platte River Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 1 quarter.
  • Platte River Capital's Impax Laboratories, Inc. position peaked at $1.2M in Q2 2013.
  • 158 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2013.

Based on Platte River Capital's 13F filing for Q3 2013, filed 8 Nov 2013.